These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 22890513

  • 1. Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil.
    Banerjee S, Pahari A, Sengupta J, Patnaik SK.
    Pediatr Nephrol; 2013 Jan; 28(1):93-7. PubMed ID: 22890513
    [Abstract] [Full Text] [Related]

  • 2. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.
    Bagga A, Hari P, Moudgil A, Jordan SC.
    Am J Kidney Dis; 2003 Dec; 42(6):1114-20. PubMed ID: 14655181
    [Abstract] [Full Text] [Related]

  • 3. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
    Kwinta-Rybicka J, Wilkosz K, Wierzchowska-Słowiacze EK, Ogarek I, Moczulska A, Stec Z, Pełkowska A, Sancewicz-Pach K, Pietrzyk JA.
    Przegl Lek; 2006 Dec; 63 Suppl 3():44-8. PubMed ID: 16898486
    [Abstract] [Full Text] [Related]

  • 4. [Mycophenolate mofetil (MMF) as the first choice immunosuppressive drug in treatment of steroid-dependent nephrotic syndrome in children].
    Ogarek I, Szczęsny-Choruz E, Wierzchowska-Słowiaczek E, Kwinta-Rybicka J, Stec Z, Moczulska A, Wilkosz K, Drożdż D.
    Pol Merkur Lekarski; 2018 Apr 23; 44(262):192-195. PubMed ID: 29775447
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
    Fujinaga S, Hirano D, Nishino T, Umeda C, Watanabe Y, Nakagawa M.
    Pediatr Nephrol; 2019 Nov 23; 34(11):2417-2421. PubMed ID: 31435725
    [Abstract] [Full Text] [Related]

  • 6. Clinical efficacy of mycophenolate mofetil versus levamisole therapy in frequently relapsing and steroid dependent childhood nephrotic syndrome - A retrospective comparative analysis.
    Sharma S, Kalra S, Shukla S, Sharma P.
    Nephrology (Carlton); 2022 Sep 23; 27(9):758-762. PubMed ID: 35619554
    [Abstract] [Full Text] [Related]

  • 7. Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome.
    Al-Akash S, Al-Makdama A.
    Ann Saudi Med; 2005 Sep 23; 25(5):380-4. PubMed ID: 16270759
    [Abstract] [Full Text] [Related]

  • 8. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.
    Mendizábal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J.
    Pediatr Nephrol; 2005 Jul 23; 20(7):914-9. PubMed ID: 15891923
    [Abstract] [Full Text] [Related]

  • 9. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome.
    Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB.
    Pediatr Nephrol; 2003 Aug 23; 18(8):833-7. PubMed ID: 12774223
    [Abstract] [Full Text] [Related]

  • 10. Switch from cyclosporine A to mycophenolate mofetil in nephrotic children.
    Ulinski T, Dubourg L, Saïd MH, Parchoux B, Ranchin B, Cochat P.
    Pediatr Nephrol; 2005 Apr 23; 20(4):482-5. PubMed ID: 15719253
    [Abstract] [Full Text] [Related]

  • 11. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center.
    Fujinaga S, Ohtomo Y, Hirano D, Nishizaki N, Someya T, Ohtsuka Y, Kaneko K, Shimizu T.
    Clin Nephrol; 2009 Oct 23; 72(4):268-73. PubMed ID: 19825332
    [Abstract] [Full Text] [Related]

  • 12. Mycophenolate mofetil for treatment of idiopathic nephrotic syndrome in children.
    Nickavar A, Safarzadeh AE, Sotoudeh K, Otukesh H, Hooman N.
    Iran J Kidney Dis; 2012 Sep 23; 6(5):346-9. PubMed ID: 22976259
    [Abstract] [Full Text] [Related]

  • 13. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K.
    BMC Nephrol; 2018 Nov 01; 19(1):302. PubMed ID: 30382824
    [Abstract] [Full Text] [Related]

  • 14. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children.
    Basu B, Babu BG, Mahapatra TK.
    Clin Exp Nephrol; 2017 Feb 01; 21(1):143-151. PubMed ID: 27108294
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of oral cyclophosphamide versus mycophenolate mofetil in childhood nephrotic syndrome: an open-label comparative study.
    Dhooria GS, Bhargava S, Bhat D, Pooni PA, Goel N, Kakkar S.
    BMC Nephrol; 2024 Sep 09; 25(1):296. PubMed ID: 39251984
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome.
    Wang J, Mao J, Chen J, Fu H, Shen H, Zhu X, Liu A, Shu Q, Du L.
    Nephrology (Carlton); 2016 Jan 09; 21(1):21-7. PubMed ID: 26697959
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.
    Sinha A, Puraswani M, Kalaivani M, Goyal P, Hari P, Bagga A.
    Kidney Int; 2019 Jan 09; 95(1):210-218. PubMed ID: 30497684
    [Abstract] [Full Text] [Related]

  • 18. Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children.
    Kang Z, Li Z, Duan C, Wu T, Xun M, Ding Y, Zhang Y, Zhang L, Yin Y.
    Pediatr Nephrol; 2015 Jul 09; 30(7):1121-9. PubMed ID: 25773534
    [Abstract] [Full Text] [Related]

  • 19. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome.
    Afzal K, Bagga A, Menon S, Hari P, Jordan SC.
    Pediatr Nephrol; 2007 Dec 09; 22(12):2059-65. PubMed ID: 17938973
    [Abstract] [Full Text] [Related]

  • 20. Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial.
    Baudouin V, Alberti C, Lapeyraque AL, Bensman A, André JL, Broux F, Cailliez M, Decramer S, Niaudet P, Deschênes G, Jacqz-Aigrain E, Loirat C.
    Pediatr Nephrol; 2012 Mar 09; 27(3):389-96. PubMed ID: 21947272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.